Health Technology Eisai Co., Ltd. Business Summary
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.
Financial Highlights
Mar 2021
JPY USD Revenue 645,942M 6,090.49M Gross Profit 465,186M 4,386.17M Operating income 56,543M 533.13M Income before tax 52,551M 495.49M Net income 42,119M 397.13M EBITDA 92,842M 875.39M Diluted EPS 146.90 1.38 Dividends Per Share 160 1.50 Total Assets 1,090.00B 9,864.33M Total liabilities 362,067M 3,276.62M Total equity 703,183M 6,363.64M Operating cash flow 73,853M 696.34M Currency in JPY Currency in USD
Historical Data Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
539,097M
600,054M
642,834M
695,621M
645,942M
Gross Profit
331,091M
386,599M
446,436M
510,352M
465,186M
Operating income
51,205M
75,595M
99,921M
138,679M
56,543M
Income before tax
57,668M
76,803M
89,454M
128,063M
52,551M
Net income
39,359M
51,845M
63,386M
121,767M
42,119M
EBITDA
77,689M
101,778M
126,762M
172,379M
92,842M
Diluted EPS
137.41
180.97
221.11
424.79
146.90
Dividends Per Share
150
150
150
160
160
Total Assets
1,030.76B
1,049.03B
1,071.52B
1,062.14B
1,090.00B
Total liabilities
428,172M
434,934M
419,539M
359,509M
362,067M
Total equity
584,630M
593,582M
628,120M
678,127M
703,183M
Operating cash flow
75,851M
149,649M
103,714M
102,782M
73,853M
Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
4,978.38M
5,414.06M
5,796.79M
6,397.94M
6,090.49M
Gross Profit
3,057.51M
3,488.14M
4,025.76M
4,693.93M
4,386.17M
Operating income
472.86M
682.06M
901.04M
1,275.49M
533.13M
Income before tax
532.54M
692.96M
806.65M
1,177.85M
495.49M
Net income
363.46M
467.77M
571.58M
1,119.94M
397.13M
EBITDA
717.43M
918.30M
1,143.08M
1,585.44M
875.39M
Diluted EPS
1.26
1.63
1.99
3.90
1.38
Dividends Per Share
1.38
1.35
1.35
1.47
1.50
Total Assets
9,250.32M
9,863.94M
9,680.80M
9,838.72M
9,864.33M
Total liabilities
3,842.51M
4,089.64M
3,790.38M
3,330.17M
3,276.62M
Total equity
5,246.61M
5,581.39M
5,674.84M
6,281.57M
6,363.64M
Operating cash flow
700.45M
1,350.22M
935.24M
945.33M
696.34M
Valuation Measures
Mar 2021
PER 50.48 ROA 3.91% ROE 6.09% Operating margin 8.75% Profit margin 6.52%
Key executives
Chief Executive Officer & Representative Director:
Haruo Naito
COO, Representative Executive Officer & Head-China:
Yasushi Okada
Chief Financial Officer:
Ryohei Yanagi
Chief Medical Officer & Managing Executive Officer:
Edward Stewart Geary
Chief Medical & Chief Clinical Officer-Neurology:
Lynn D. Kramer Shareholders
Wellington Management Co. LLP (8.6%)
Nomura Asset Management Co., Ltd. (6.1%)
Government of Japan (5.0%)
Nippon Life Insurance Co. (3.8%)
Eisai Co., Ltd. (3.3%)
Asset Management One Co., Ltd. (3.0%)
Daiwa Asset Management Co. Ltd. (2.8%)
Nikko Asset Management Co., Ltd. (2.8%)
The Vanguard Group, Inc. (2.1%)
Resona Holdings, Inc. (2.1%)
Contact Details Website: http://www.eisai.co.jp Address:
4-6-10 Koishikawa,
Bunkyo-Ku,
Tokyo,
112-8088,
Japan
Phone:
+81.3.3817.3700
Related Companies
Eisai Innovation, Inc.
Eisai Europe Ltd.
Eisai LLC
Eisai Machinery China Co. Ltd.
Eisai Laboratorios S de RL de CV
Eisai GesmbH
Eisai Farmaceutica, Unipessoal Lda.
Eisai Clinical Research Singapore Pte Ltd.
Eisai Ltd. (Canada)
Eisai SA/NV
Eisai (Malaysia) Sdn. Bhd.
Eisai (Thailand) Marketing Co., Ltd.
Eisai AB
Eisai Pharma AG
Eisai (Singapore) Pte Ltd.
Eisai Co. Ltd. /Misato Factory/
Eisai Board Incentive Plan
Eisai Corporate Pension Fund
Eisai Pension Fund
Eisai China, Inc.
H3 Biomedicine, Inc.
Eisai R&D Management Co., Ltd.
Herusu Co., Ltd.
Gakuen Shoji Co., Ltd.
PT Eisai Indonesia
Eisai Taiwan, Inc.
Eisai (Hong Kong) Co., Ltd.
Eisai Australia Pty Ltd.
Eisai Pharmaceuticals India Pvt Ltd.
Eisai GmbH
Competitors
JW Holdings Corporation
Ipsen SA
Denali Therapeutics Inc.
Codiak BioSciences, Inc.
Mirati Therapeutics Inc.
Exelixis, Inc.
Seagen, Inc.
Blueprint Medicines Corp.
Arcutis Biotherapeutics Inc
Aprea Therapeutics, Inc.
Deciphera Pharmaceuticals, Inc.
Genkyotex SA
Aeolus Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc.
AC Immune SA
Cortexyme, Inc.
Vivoryon Therapeutics N.V.
Calithera Biosciences, Inc.
Epizyme, Inc.
Xenon Pharmaceuticals Inc.
Aptinyx Inc
TCR2 Therapeutics, Inc.
Oncternal Therapeutics, Inc.
Hanall Biopharma Co., Ltd.
AVEO Pharmaceuticals, Inc.
Rain Therapeutics Inc
Relay Therapeutics, Inc.
Cassava Sciences, Inc.
Marinus Pharmaceuticals Inc
Copyright © 2021 FactSet Research Systems Inc. All rights reserved.
Last Updated on 15 Oct, 2021
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
